Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652162 | 0.87 | ACHE (0.52) | CXCR4ALDH1A1ATMDRD4ACHE | |
| SCHEMBL19658602 | 0.87 | CXCR4 (0.59) | CXCR4ALDH1A1ATMDRD2DRD4 | |
| SCHEMBL19658607 | 0.85 | CXCR4 (0.56) | CXCR4ALDH1A1ATMDRD2DRD4 | |
| SCHEMBL19652181 | 0.82 | ACHE (0.50) | ALDH1A1ACHE | |
| SCHEMBL19652161 | 0.80 | ACHE (0.50) | ACHEFAAH | |
| SCHEMBL19652180 | 0.80 | HTT (0.55) | CXCR4ALDH1A1ATMDRD2DRD4 | |
| SCHEMBL19652184 | 0.79 | ACHE (0.51) | ACHE | |
| SCHEMBL17754048 | 0.78 | CXCR4 (0.60) | CXCR4ALDH1A1ATMDRD2DRD4 | |
| SCHEMBL18768411 | 0.76 | LMNA (0.48) | CXCR4ALDH1A1ATMDRD2DRD4 | |
| SCHEMBL28910476 | 0.74 | CXCR4 (0.61) | CXCR4ALDH1A1ATMDRD4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CXCR4 796/4885ALDH1A1 1563/4885ATM 1939/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CXCR4 796/4885ALDH1A1 1563/4885ATM 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.